Charles River Laboratories International (CRL) Gains from Investment Securities (2021 - 2023)

Charles River Laboratories International's Gains from Investment Securities history runs 3 years deep, the most recent figure standing at $1.8 million for Q3 2023.

• In Q3 2023, Gains from Investment Securities rose 115.12% year-over-year to $1.8 million; the TTM figure through Dec 2023 stood at $1.8 million (up 148.23% YoY), while the FY2023 annual figure was $1.8 million, up 148.23% from the prior year.
• Gains from Investment Securities for Q3 2023 stood at $1.8 million, down from $11.7 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $11.7 million in Q4 2022, with the low at -$23.9 million in Q4 2021.
• The 3-year median for Gains from Investment Securities is -$6.9 million (2021), against an average of -$6.0 million.
• The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities soared 148.73% in 2022, then soared 115.12% in 2023.
• Charles River Laboratories International's Gains from Investment Securities stood at -$23.9 million in 2021, then jumped by 148.73% to $11.7 million in 2022, then sank by 84.49% to $1.8 million in 2023.
• Business Quant data shows CRL's Gains from Investment Securities at $1.8 million in Q3 2023, $11.7 million in Q4 2022, and -$12.0 million in Q2 2022.